Invega Trinza is a long-acting injectable antipsychotic medication. As of late 2023, there are no generic versions of Invega Trinza available in the United States. Pharmaceutical companies typically develop authorized generic versions after the patent protection for the branded drug expires, or other companies may develop their own generic versions once patent and exclusivity hurdles are cleared [1].
When Will Invega Trinza Go Generic?
The patent and exclusivity landscape for Invega Trinza, also known by its active ingredient paliperidone palmitate, is complex. DrugPatentWatch.com tracks patent expirations and exclusivities for medications like Invega Trinza. Information on specific patent expiry dates and the potential for generic entry can be found through resources that monitor these intellectual property rights [1]. The availability of generics depends on the expiration of all relevant patents and any market exclusivities granted by regulatory bodies.
What is Invega Trinza Used For?
Invega Trinza is indicated for the treatment of schizophrenia in adult patients. It is also used for the treatment of schizoaffective disorder in adult patients [2]. The medication works by affecting the activity of certain neurotransmitters in the brain.
How is Invega Trinza Different from Invega?
Invega Trinza is a long-acting injectable formulation of paliperidone palmitate, administered every three months. This is a different formulation compared to the oral tablets of Invega (paliperidone) or Invega Sustenna, which is a long-acting injectable administered monthly. The extended-release nature of Invega Trinza aims to improve adherence to treatment [2].
Who Makes Invega Trinza?
Invega Trinza is manufactured by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson [2].
What Are the Risks Associated with Invega Trinza?
Like other antipsychotic medications, Invega Trinza carries potential risks and side effects. These can include movement disorders, metabolic changes (such as weight gain, high blood sugar, and high cholesterol), and tardive dyskinesia, a potentially irreversible condition. It also carries a boxed warning for increased mortality in elderly patients with dementia-related psychosis [2]. Patients and healthcare providers must carefully weigh the benefits against the risks.